Conquering Diseases

Study Of An Investigational Drug For Relapsed Or Refractory Cd22+ B-Acute Lymphoblastic Leukemia (B All)

Description

Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.

Overview

We are studying whether the investigational drug when used with chemotherapy will be well tolerated and effective against B-Acute Lymphoblastic Leukemia (B ALL). Participants will receive up to six one-month cycles of treatment and then have their health followed for up to 5 years.

What we're hoping for

To see if Children and Young Adults whose B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) will respond to the investigational drug. We will also record any side effects.

Additional Information

ClinicalTrials.gov Identifier: NCT02981628

 Principal Investigator

Stefanie  Lowas, MD

University of Massachusetts Medical School

 Study Contact

Danielle  Pichette-Patsky

+1 508-856-3077

Danielle.Pichette-Patsky@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989